Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
MRNA rose 31% over 21 days to a period high, supported by positive Phase 3 melanoma results with Merck, expected additional oncology data, and recent FDA approvals for updated respiratory vaccines.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠High Cash Burn ⢠Weak Profitability MRNA's strong liquidity and moderate leverage provide runway, but steep cash burn, collapsing revenue, and deeply negative profitability make the stock highly dependent on a turnaround.
Price Behavior
Key Price Behavior Insights: ⢠Volatile rebound ⢠Resistance test ⢠Support critical Support Level: $145â$147 (stronger: $135â$140) Resistance Level: $158â$159 MRNA's rebound is cautiously bullish with RSI near 62, but a decisive break above $158â$159 is needed to extend gains while $145â$147 support must hold.
Sentiment & News
Key News Insights: ⢠Phase 3 success ⢠Oncology expansion ⢠Mixed sentiment Moderna's strong cancer-trial results have shifted investor focus toward oncology growth, though commercialization risks, competition, and mixed analyst sentiment remain.
AI Summary
Moderna is now an oncology-optionality investment centered on whether intismeran/KEYTRUDA can become a scalable, approved cancer franchise, but at roughly $22 billion the shares already price substantial success despite steep cash burn and a declining COVID baseâfavor regulatory and launch proof before adding exposure.
Description
Moderna, Inc. develops and commercializes messenger RNA-based therapeutics and vaccines for infectious diseases, oncology, rare disorders, cardiovascular conditions, and autoimmune diseases across the United States, Europe and other markets. Its pipeline includes respiratory, latent and public health vaccines along with systemic, localized and inhaled therapeutic candidates for oncology and other indications. The company collaborates with multiple pharmaceutical and government partners â including AstraZeneca, Merck, Vertex, DARPA and the Bill & Melinda Gates Foundation â and was founded in 2010, with headquarters in Cambridge, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 22 | Sep 29 | MRNA | Moderna, Inc. | MRNA rose 31% over 21 days to a period high, supported by positive Phase 3 melanoma results with Merck, expected additional oncology data, and recent FDA approvals for updated respiratory vaccines. | Active | +0.0% |